Analyst Actions -- 9/22/2011

 | Sep 22, 2011 | 12:19 PM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

intc

,

jnj

,

wag

,

hnz

,

hsy

,

fdo

,

deck

,

brcm

,

bmy

,

bsx

,

stj

,

crm

,

bbby

Accenture estimates raised at UBS

ACN estimates increased through 2011, UBS said.  F12 revenue and EPS guidance likely to be maintained.  Maintain $64 price target and Buy rating.

-----

Adobe Systems estimates, target increased at Citigroup

Shares of ADBE now seen reaching $34, according to Citigroup.  Estimates also raised as underappreciated secular value.

-----

Athenahealth downgraded at JP Morgan

ATHN was downgraded from Neutral to Underweight, JP Morgan said. Valuation call, based on a $50 price target.

-----

Bed, Bath & Beyond estimates raised at Sterne Agee

BBBY estimates were increased through 2012, Sterne Agee said. Company is cutting operating costs. Neutral rating.

-----

Boston Scientific rated new Hold at Kaufman

BSX was initiated with a Hold rating, Kaufman Bros. said. $7 price target. Company has still yet to show meaningful sales and earnings growth.

-----

Bristol-Myers upgraded at Goldman

BMY was upgraded from Neutral to Buy, Goldman Sachs said. $37 price target. Company has the best long-term earnings visibility in the group.

-----

Broadcom upgraded at JMP

BRCM was upgraded to Market Perform, JMP Securities said. Industry checks suggest better sales prospects.

-----

Conagra Foods rated new Hold at Jefferies

Coverage of CAG was started with a Hold rating, Jefferies said. $25 price target. Visibility is cloudy, given the failed RAH bid.

-----

Cubist Pharmaceuticals upgraded at BofA/Merrill

CBST was upgraded to Buy, Bank of America/Merrill Lynch said. $45 price target. Cubicin recently received a patent extension.  

-----

CVS Caremark rated new Hold at Deutsche

Coverage of CVS was started with a Hold rating, Deutsche Bank said. Valuation call, based on a $38.50 price target.

-----

Deckers Outdoor rated new Buy at Auriga

Coverage of DECK was started with a Buy rating, Auriga said. $115 price target. Earnings expectations appear conservative for the near-term.

-----

Diamond Foods downgraded at Jefferies

DMND was downgraded to Hold, Jefferies said. Valuation call, based on a $94 price target.

-----

Dollar General rated new Buy at Guggenheim

DG was initiated with a Buy rating, Guggenheim said. $44 price target. Company should continue to expand its margins over the next several quarters.

-----

Edwards Lifesciences target upped at Jefferies

EW target was boosted to $94, Jefferies said. Company can generate significant earnings growth over the next few years.

-----

Family Dollar rated new Buy at Guggenheim

Coverage of FDO was started with a Buy rating, Guggenheim said. Company should continue to deliver solid growth and generate steady cash flow. $62 price target.

-----

Hershey rated new Hold at Jefferies

HSY was initiated with a Hold rating, Jefferies said. Valuation call, based on a $58 price target.

-----

HJ Heinz rated new Buy at Jefferies

HNZ was initiated with a Buy rating, Jefferies said. $59 price target. Company is leveraged to emerging market growth.

-----

Hologic rated new Buy at Kaufman

Coverage of HOLX was started with a Buy rating, Kaufman Bros. said. $19 price target. New products should help drive growth in the coming quarters.

-----

Intel upgraded at BofA/Merrill

INTC was upgraded to Buy, Bank of America/Merrill Lynch said. $27 price target. Estimates also boosted, as the company is seeing margin expansion.  

-----

Intuit target boosted at Jefferies

Shares of INTU now seen reaching $55, according to Jefferies. Company can deliver double-digit organic annual sales growth in the coming years. Buy rating.

-----

Johnson & Johnson downgraded at Goldman

JNJ was downgraded from Buy to Neutral, Goldman Sachs said. Valuation call, based on a $74 price target.

-----

Las Vegas Sands estimates, target increased at Citigroup

Shares of LVS now seen reaching $59, according to Citigroup.  Estimates also raised to reflect GGR trends and improved VIP outlook.  Buy rating.

-----

Lennar upgraded at Citigroup

LEN was upgraded from Hold to Buy, Citigroup said.  $22 price target.  Attractive valuation and seasonal homebuilder benefits.

-----

Lululemon Athletica rated new Buy at Argus

LULU was initiated with a Buy rating, Argus Research said. $75 price target. Company can continue to deliver 30% annual sales growth.

-----

Mako Surgical cut from Conviction Buy List at Goldman

MAKO was removed from the Conviction Buy list, according to Goldman Sachs. Valuation call, based on a $44 price target.

-----

Netflix upgraded at UBS

NFLX was upgraded from Sell to Neutral, UBS said.  $130 price target.  Valuation at more reasonable level after correction.

-----

New York Times estimates, target lowered at UBS

Shares of NYT now seen reaching $7, according to UBS.  Estimates also lowered on weaker than expected 3Q guidance.  Neutral rating.

-----

Red Hat estimates, target raised at Citigroup

Shares of RHT now seen reaching $48, according to Citigroup.  Estimates also increased on higher guidance.  Buy rating.

-----

Red Hat estimates increased at Morgan Stanley

RHT estimates were raised through 2013, Morgan Stanley said. Billings growth is accelerating. Overweight rating and $50 price target.

-----

Red Hat estimates increased at UBS

RHT estimates increased through 2013, UBS said.  Strength across all metrics.  Maintain $54 price target and Buy rating. 

-----

Salesforce.com estimates cut at Jefferies

CRM estimates were reduced through 2012, Jefferies said. Assistly acquisition will dilute near-term earnings. Buy rating and $156 price target.

-----

St. Jude rated new Buy at Kaufman

Coverage of STJ was started with a Buy rating, $50 price target. Company is taking market share, but overall business growth is slowing.

-----

Stryker rated new Buy at Kaufman

SYK was initiated with a Buy rating, Kaufman Bros. said. $57 price target. Company has multiple growth drivers and should continue to generate solid cash flow.

-----

Tesla Motors rated new Outperform at Baird

TSLA was initiated with an Outperform rating, Robert Baird said. $35 price target. Company continues to differentiate itself from the competition.

-----

Walgreens rated new Hold at Deutsche

WAG was initiated with a Hold rating, Deutsche Bank said. $38.50 price target. ESRX dispute could continue to hang over the stock.

-----

Yahoo upgraded at Stifel

YHOO was upgraded from Hold to Buy, Stifel Nicolaus said. $18 price target. Likelihood of a buyout has improved to 80%.

-----

Zimmer rated new Hold at Kaufman

ZMH was initiated with a Hold rating, Kaufman Bros. said. $57 price target. Orthopedic market has lackluster growth potential.

Columnist Conversations

Volume in the SPY today was nearly double its 50 day average of volume. (The graph at the bottom of the chart ...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
Market got beat like a rented mule today as equities posted their second worst day of the year. Geopolitical ...
down 302 now, at 16577 the dow 30 is unchanged for 2014. roll the media hype!

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.